Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) expects a net profit attributable to shareholders of 31.2 million to 38.1 million yuan for 2025, representing a year-on-year growth of 82.64% to 123.03% [1] Group 1: Financial Performance - The net profit excluding non-recurring gains and losses is projected to be between 20.9 million and 25.6 million yuan, indicating a significant year-on-year increase of 321.59% to 416.40% [1] - Non-recurring gains and losses are estimated to impact net profit by approximately 12 million yuan, primarily from project subsidies and investment income [1] Group 2: Business Development - The company continues to deepen its main business layout centered on "drug design as the core driver and one-stop service as the strategic leader," leading to a positive overall operational outlook for 2025 [1] - Revenue from drug discovery, process research and development, and commercial production has all seen year-on-year growth [1] - The capacity utilization rates of its wholly-owned subsidiaries, Shanghai Hongbo Shangyi Pharmaceutical Technology Co., Ltd. and Chengdu Hongbo Zhiyuan Pharmaceutical Technology Co., Ltd., have improved compared to the previous year [1] Group 3: Strategic Initiatives - The company has enhanced platform construction and continuously improved its industry chain service system, significantly boosting its one-stop comprehensive service capability from new drug discovery to commercial production [1] - These efforts have further consolidated the company's strategic competitive advantage [1]
泓博医药(301230.SZ)：预计2025年净利润同比增长82.64%～123.03%